2Connexins in neurons and glia：targets for intervention in disease and injuryINVITED REVIEWS1013-1017
4Glycogen and amyloid-beta：key players in the shift from neuronal hyperactivity to hypoactivity observed in Alzheimer’s disease?HIGHLIGHTS1023-1025
5Role of mitochondria in regulating microRNA activity and its relevance to the central nervous systemHIGHLIGHTS1026-1028
10“To measure is to know”：how advances in image analysis are supporting neural repair strategiesPERSPECTIVES1040-1042
11Argon：a novel therapeutic option to treat neuronal ischemia and reperfusion injuries?PERSPECTIVES1043-1044
14Streptozotocin induced Alzheimer’s disease like changes and the underlying neural degeneration and regeneration mechanismPERSPECTIVES1050-1052
15Gene therapy in Parkinson’s disease:targeting the endplasmic reticulum proteostasis networkPERSPECTIVES1053-1054
16Glucagon peptide-like 1 receptor (GLP-1R) expressionper se：a new insight into neurodegenerative disease?PERSPECTIVES1055-1057
17Minimally manipulated autologous adherent bone marrow cells (ABMCs):a promising cell therapy of spinal cord injur yPERSPECTIVES1058-1060
18Provision of nutrients after acute spinal cord injury：the implications of feast and faminePERSPECTIVES1061-1062
19Potential of the use of an antioxidant compound to promote peripheral nerve regeneration after injuryPERSPECTIVES1063-1064
20Metallic nanoparticles for peripheral nerve regeneration：is it a feasible approach?PERSPECTIVES1065-1066
